MetaCap

Pyxis Oncology (PYXS) vs Rocket Pharmaceuticals (RCKT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rocket Pharmaceuticals (RCKT) has outperformed Pyxis Oncology (PYXS) over the past year, losing 33.4% versus a loss of 62.3%. Over five years, PYXS leads with a -85.9% price change compared with -91.8% for RCKT. Rocket Pharmaceuticals is the larger company by market cap ($217.7 million vs $216.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PYXS-62.29%RCKT-33.45%
+89%+1%-86%
Nov 21, 20251 yearNov 20, 2026
PYXS-85.99%RCKT-93.00%
+15%-42%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PYXS versus RCKT key metrics
MetricPYXSRCKT
Share price$1.81$1.95
Market cap$216.49M$217.74M
1-day change+7.74%-7.58%
YTD return+57.39%-44.44%
1-year return-62.29%-33.45%
5-year return-85.90%-91.76%
EPS (TTM)$-1.27$-0.15
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$13.86M$0
Revenue growth (YoY)-14.17%—
Net income (latest FY)$-79.62M$-223.12M
Gross margin82.77%—
Operating margin-609.18%—
Net margin-574.55%—
52-week high$5.55$5.45
52-week low$1.03$1.94
Distance from 52-week high-67.39%-64.22%
Analyst consensusstrong_buybuy
Avg. price target upside+354.14%+326.15%
Average volume1.06M1.90M
Shares outstanding119.61M111.66M
Employees56202
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RCKT has outperformed PYXS by 28.8 percentage points over the past year.

About Pyxis Oncology

PYXS stock →

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

About Rocket Pharmaceuticals

RCKT stock →

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 202 employees

PYXS vs RCKT FAQ

Which is bigger, Pyxis Oncology or Rocket Pharmaceuticals?

Rocket Pharmaceuticals (RCKT) is larger, with a market capitalization of $217.74M compared with $216.49M for Pyxis Oncology (PYXS).

Which stock has performed better over the past year, PYXS or RCKT?

RCKT returned -33.45% over the past 12 months, compared with -62.29% for PYXS (price return, excluding dividends). Past performance does not predict future results.

Are Pyxis Oncology and Rocket Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons